Docetaxel resistance can develop through numerous mechanisms, including androgen receptor (AR) signalling (Seruga et al., 2011), activation of prosurvival pathways (McCubrey et al., 2007) and the acquisition of a cancer stem cell (CSC) morphology (Seruga et al., 2011). Here, AR is linked to cancer.